• David Frame, Gianni B Scappaticci, Thomas M Braun, Mary Maliarik, Thomas H Sisson, Steven W Pipe, Daniel A Lawrence, Paul G Richardson, Michael Holinstat, Robert C Hyzy, Daniel R Kaul, Kevin S Gregg, Vibha N Lama, and Gregory A Yanik.
• Blood and Marrow Transplant Program, Michigan Medicine, Ann Arbor, MI; Department of Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI.
• Chest. 2022 Aug 1; 162 (2): 346355346-355.

BackgroundSARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties.Research QuestionWhat is the safety and tolerability of defibrotide in patients with severe SARS-CoV-2 infections?Study Design And MethodsWe report a prospective, open-label, single-center safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible participants were 18 years of age or older with clinical and radiographic signs of ARDS, no signs of active bleeding, a serum D-dimer of more than twice upper limit of normal, and positive polymerase chain reaction-based results for SARS-CoV-2. Defibrotide (6.25 mg/kg/dose IV q6h) was administered for a planned 7-day course, with serum D-dimer levels and respiratory function monitored daily during therapy.ResultsTwelve patients (median age, 63 years) were treated, with 10 patients receiving mechanical ventilation and 6 receiving vasopressor support at study entry. The median D-dimer was 3.25 μg/ml (range, 1.33-12.3) at study entry. The median duration of therapy was 7 days. No hemorrhagic or thrombotic complications occurred during therapy. No other adverse events attributable to defibrotide were noted. Four patients met the day 7 pulmonary response parameter, all four showing a decrease in serum D-dimer levels within the initial 72 h of defibrotide therapy. Three patients died of progressive pulmonary disease 11, 17, and 34 days after study entry. Nine patients (75%) remain alive 64 to 174 days after initiation of defibrotide. Day 30 all-cause mortality was 17% (95% CI, 0%-35%). All patients with a baseline Pao2 to Fio2 ratio of ≥ 125 mm Hg survived, whereas the three patients with a baseline Pao2 to Fio2 ratio of < 125 mm Hg died.InterpretationThe use of defibrotide for management of SARS-CoV-2-related ARDS proved safe and tolerable. No hemorrhagic or thrombotic complications were reported during therapy, with promising outcomes in a patient population with a historically high mortality rate.Trial RegistryClinicalTrials.gov; No.: NCT04530604; URL: www.Clinicaltrialsgov.Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

18 keywords...

hide…